Trial Profile
A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nassopahryngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Cisplatin
- Indications Head and neck cancer; Oropharyngeal cancer
- Focus Adverse reactions
- 19 Dec 2018 Results published in the Investigational New Drugs
- 07 Jun 2016 Status changed from recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology